Meningitis B Vaccine To Be Offered To Some University Of Kent Students Amid Deadly Outbreak

Meningitis B vaccine to be offered to some University of Kent students amid deadly outbreak Health officials in the United Kingdom have announced that the Meningitis B (MenB) vaccine will be offered to some students at the University of Kent as part of a “targeted” vaccination programme aimed at tackling a deadly outbreak of meningococcal disease. The plan, confirmed by the UK’s health secretary, Wes Streeting, comes as the UK Health Security Agency (UKHSA) responds to an outbreak in the Canterbury, Kent area that has been linked to a cluster of cases among young people, particularly university student The meningitis outbreak, involving invasive meningococcal disease, has so far resulted in the deaths of two young people, and several others have been diagnosed or are being treated. UKHSA officials have identified some of the cases as caused by meningitis B, a strain against which many older teenagers and young adults are not routinely vaccinated under the current NHS schedule. In recent days, students at the University of Kent have been queuing to receive antibiotics offered as a precautionary measure to people who may have been in close contact with infected individuals while health authorities monitor the situation closely. Streeting told lawmakers that, in light of the outbreak, health officials will launch a small, targeted MenB vaccination programme beginning in the coming days, initially for students who live in halls of residence on the University of Kent’s Canterbury campus. This approach is intended to protect those most likely to have been exposed and reduce the risk of further serious illness. He also said that the eligibility for routine meningitis vaccinations which currently cover infants but not most older teenagers or young adults would be reviewed by independent health advisers to determine whether broader vaccination recommendations are needed.

The MenB vaccine was added to the NHS immunisation schedule for infants in 2015, but young adults and students born before then have generally not received it as a matter of course. This means a large proportion of university‑age people remain unprotected unless they have had the vaccine privately.

Pharmacies have seen increased demand for private MenB doses amid the outbreak, and some have reported dwindling supplies as families and students seek vaccination while the outbreak continues to be managed. Health agencies continue to urge vigilance for symptoms of meningitis and meningococcal disease including fever, headache, stiff neck, rash, and sensitivity to light and to seek urgent medical care if symptoms appear.